Zevin Asset Management buys $11,559,520 stake in AbbVie Inc (ABBV)

AbbVie Inc (ABBV) : Zevin Asset Management scooped up 1,388 additional shares in AbbVie Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 8, 2016. The investment management firm now holds a total of 172,659 shares of AbbVie Inc which is valued at $11,559,520.AbbVie Inc makes up approximately 3.10% of Zevin Asset Management’s portfolio.

Other Hedge Funds, Including , Navellier Associates Inc boosted its stake in ABBV in the latest quarter, The investment management firm added 7,507 additional shares and now holds a total of 17,023 shares of AbbVie Inc which is valued at $1,133,221. AbbVie Inc makes up approx 0.17% of Navellier Associates Inc’s portfolio.Calamos Advisors reduced its stake in ABBV by selling 1,138,822 shares or 67.16% in the most recent quarter. The Hedge Fund company now holds 556,987 shares of ABBV which is valued at $36,148,456. AbbVie Inc makes up approx 0.33% of Calamos Advisors’s portfolio.Independent Portfolio Consultants reduced its stake in ABBV by selling 1,980 shares or 16.49% in the most recent quarter. The Hedge Fund company now holds 10,025 shares of ABBV which is valued at $637,189. AbbVie Inc makes up approx 0.19% of Independent Portfolio Consultants’s portfolio.Partnerre Asset Management Corp reduced its stake in ABBV by selling 200 shares or 1.8% in the most recent quarter. The Hedge Fund company now holds 10,893 shares of ABBV which is valued at $692,359. AbbVie Inc makes up approx 0.35% of Partnerre Asset Management Corp’s portfolio.

AbbVie Inc opened for trading at $67.47 and hit $68.1239 on the upside on Monday, eventually ending the session at $67.39, with a gain of 0.30% or 0.2 points. The heightened volatility saw the trading volume jump to 52,15,360 shares. Company has a market cap of $109,747 M.

On the company’s financial health, AbbVie Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $1.20. The company had revenue of $6452.00 million for the quarter, compared to analysts expectations of $6207.43 million. The company’s revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.08 EPS.

Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by Morgan Stanley to ” Equal-Weight” on Jun 8, 2016.

AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.

Leave a Reply

AbbVie Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on AbbVie Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.